UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/575,753	01/03/2007	Martin Widschwendter	47675-183	6853
	7590 06/26/200 HT TREMAINE, LLP/	EXAMINER		
1201 Third Avenue, Suite 2200			BAUSCH, SARAE L	
SEATTLE, WA 98101-3045			ART UNIT	PAPER NUMBER
			1634	
			MAIL DATE	DELIVERY MODE
			06/26/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
Office Action Comments	10/575,753	WIDSCHWENDTER, MARTIN					
Office Action Summary	Examiner	Art Unit					
	Sarae Bausch PhD	1634					
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet with the	correspondence address					
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory perion. - Failure to reply within the set or extended period for reply will, by stat Any reply received by the Office later than three months after the may earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICATION 1.136(a). In no event, however, may a reply be od will apply and will expire SIX (6) MONTHS fround tute, cause the application to become ABANDON	DN. timely filed m the mailing date of this communication. IED (35 U.S.C. § 133).					
Status							
1)⊠ Responsive to communication(s) filed on <u>13</u>	April 2006						
· _ ·	his action is non-final.						
	,—						
· — · · ·	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims	,						
4)⊠ Claim(s) <u>1-57</u> is/are pending in the application	on						
,—	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
	6) Claim(s) is/are rejected.						
· · · · — · ·	7) Claim(s) is/are objected to.						
8)⊠ Claim(s) <u>1-57</u> are subject to restriction and/or election requirement.							
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some coll None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summal Paper No(s)/Mail 5) Notice of Informal 6) Other:						

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7, 9-17, 30-52, drawn to a method of determining methylation pattern in a gene.

Group II, claim(s) 18-23, 26-29, 53-54 drawn to nucleic acids.

Group III, claim(s) 24, 55-57 (in part as it reads on nucleic acids) drawn to use of nucleic acids. Group IV, claim(s) 25, drawn to method of manufacturing an array.

Group V, claim(s) 55-57 (in part as it reads on method) drawn to a use for the method of determining methylation patterns.

2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is analysis of methylation pattern of RASSF1A. Burbee et al. (J. Nat. Cancer Inst., 2001, vol. 93, pp. 691-9, cited on IDS) teach hypermethylation of RASSF1A in non small cell lung cancer (see abstract and figure 4). Thus, the technical feature linking the recited groups I-V does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Application/Control Number: 10/575,753 Page 3

Art Unit: 1634

Further Restriction Requirement

3. Each group named above is subject to further restriction. Applicant is required to further elect a specific gene and corresponding SEQ ID NO or a specific combination of gene and SEQ ID NO to which the claims will be limited to. This is NOT an election of species. The claims are written in Markush-type format. According to PCT Rule 13.2 and to the guidelines in Section (f)(i)(A) and Section (f)(i)(B)(1) of Annex B of the PCT Administrative instructions, all alternatives of a Markush group must have a common property or activity and a common structure. The nucleic acid sequences of the abovementioned claims each have a different chemical structure and do not share a common structure. Furthermore, the nucleic acid sequences do not share a common property or activity. Upon election of any group that contains any of the aforementioned claims, Applicant is required to elect one of the members of the group set forth in the claim, as set forth above. This is not an election of species, but rather an election of a distinct invention, owing to the functional differences between the members of the Markushlike group. Absent evidence to the contrary, each such nucleotide sequences are presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 USC 121 and 37 CFR 1.141. By statute, "[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions." 35 U.S.C. 121. Pursuant to this statute, the rules provide that "[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant... to elect that invention to which his claim shall be restricted." 37 CFR 1.142 (a). See also 37 CFR 1.141(a). It is noted that claims encompass many subcombinations usable together in a single combination and also separately usable. The

Application/Control Number: 10/575,753

Art Unit: 1634

subcombinations are separately usable as evidenced by their presentation in the alternative within the claims. Further, subcombination have separate utility and thus are distinct. Therefore, applicant is required to elect a single invention, corresponding to the elected group. Where applicant elects a subcombination and claims thereto are subsequently found allowable, any claim(s) depending from or otherwise requiring all the limitations of the allowable subcombination will be examined for patentability in accordance with 37 CFR 1.104. See MPEP § 821.04(a).

Page 4

- 4. It is noted that claim 8 has not been placed in a group, claim 8 is an improper multiple dependent claim. If applicant amends the improper multiple dependencies, the claim will be placed in the appropriate group.
- 5. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

6. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed to a nonelected

Art Unit: 1634

process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarae Bausch whose telephone number is (571) 272-2912. The examiner can normally be reached on M-F 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James (Doug) Schultz can be reached on (571) 272-0763. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application

Application/Control Number: 10/575,753 Page 6

Art Unit: 1634

or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Sarae Bausch/ Primary Examiner, Art Unit 1634